Last reviewed · How we verify

Diabyl — Competitive Intelligence Brief

Diabyl (GLICLAZIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: gliclazide. Area: Metabolic.

marketed gliclazide Sulfonylurea receptor 1, Kir6.2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Diabyl (GLICLAZIDE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diabyl TARGET GLICLAZIDE marketed gliclazide Sulfonylurea receptor 1, Kir6.2
Starlix NATEGLINIDE Novartis marketed Glinide [EPC] Sulfonylurea receptor 1, Kir6.2 2000-01-01
Amaryl GLIMEPIRIDE Sanofi marketed Sulfonylurea [EPC] Sulfonylurea receptor 1, Kir6.2 1995-01-01
Glucotrol GLIPIZIDE Pfizer marketed Sulfonylurea [EPC] Sulfonylurea receptor 1, Kir6.2 1984-01-01
Micronase glibenclamide Sanofi marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1984-01-01
Proglycem DIAZOXIDE marketed diazoxide Sulfonylurea receptor 1, Kir6.2 1973-01-01
Dymelor ACETOHEXAMIDE Eli Lilly marketed acetohexamide Sulfonylurea receptor 1, Kir6.2 1964-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (gliclazide class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diabyl — Competitive Intelligence Brief. https://druglandscape.com/ci/gliclazide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: